Development of a quality-of-life instrument for autoimmune bullous disease: The autoimmune bullous disease quality of life questionnaire

JAMA Dermatology

Volumn 149, Issue 10, 2013, Pages 1186-1191

  Sebaratnam, Deshan F ^a   Hanna, Anna Marie ^a   Chee, Shien Ning ^a   Frew, John W ^a   Venugopal, Supriya S ^a   Daniel, Benjamin S ^a   Martin, Linda K ^a   Rhodes, Lesley M ^a   Tan, Jeremy Choon Kai ^a   Wang, Charles Qian ^a   Welsh, Belinda ^b   Nijsten, Tamar ^c   Murrell, Dédée F ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNE BULLOUS DISEASE QUALITY OF LIFE QUESTIONNAIRE; AUTOIMMUNE BULLOUS DISEASE SKIN DISORDER INTENSITY SCORE; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CONTENT VALIDITY; CONTROLLED STUDY; CONVERGENT VALIDITY; DERMATOLOGY LIFE QUALITY INDEX; DISCRIMINANT VALIDITY; EPIDERMOLYSIS BULLOSA ACQUISITA; FACE VALIDITY; FEMALE; HUMAN; LINEAR IGA BULLOUS DERMATOSIS; MAJOR CLINICAL STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PEMPHIGUS; PEMPHIGUS DISEASE AREA INDEX; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SENSITIVITY ANALYSIS; SHORT FORM 36; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SKIN DISEASES, VESICULOBULLOUS; YOUNG ADULT;

EID: 84885928285     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.4972     Document Type: Article

References (21)

1. Wiebe S, Guyatt G,Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56(1): 52-60.
2. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3): 210-216.
3. Tabolli S, Mozzetta A, Antinone V, Alfani S, Cianchini G, Abeni D. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-Item Short Form Health Survey questionnaire. Br J Dermatol. 2008;158(5): 1029-1034.
4. Terrab Z, Benchikhi H, Maaroufi A, Hassoune S, Amine M, Lakhdar H. Quality of life and pemphigus [in French]. Ann Dermatol Venereol. 2005;132(4): 321-328.
5. Paradisi A, Sampogna F, Di Pietro C, et al. Quality-of-life assessment in patients with pemphigus using aminimum set of evaluation tools. J AmAcad Dermatol. 2009;60(2): 261-269.
6. Darjani A, Ghanbari A, Sayadi Nejhad A. Comparison of the health-related quality of life of patients suffering from pemphigus with healthy people. J Guilan Univ Med Sci. 2008;17(67): 1-9.
7. Mayrshofer F, Hertl M, Sinkgraven R, et al. Significant decrease in quality of life in patients with pemphigus vulgaris: results from the German Bullous Skin Disease (BSD) Study Group [in German]. J Dtsch Dermatol Ges. 2005;3(6): 431-435.
8. Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, Valikhani M, Esmaili N. Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. J Dermatol. 2012;39(2): 141-144.
9. Masahiro S, Shigaku I, Yutaka I, Ogawa H. An investigation of quality of life (QOL) of pemphigus patients in Japan (first report). J Dermatol. 2000;110(3): 283-288.
10. Sebaratnam DF, McMillan JR,Werth VP, Murrell DF. Quality of life in patients with bullous dermatoses. Clin Dermatol. 2012;30(1): 103-107.
11. Sebaratnam DF, Frew JW, Davatchi F, Murrell DF. Quality-of-life measurement in blistering diseases. Dermatol Clin. 2012;30(2): 301-307; ix.
12. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol. 1990;123(6): 751-756.
13. Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161(6): 1323-1330.
14. Murphy B, Cockborun J, MurphyM. Focus groups in health research. Health Promot J Austr. 1992;2(2): 37-41.
15. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6): 803-807.
16. Costello AB, Osborne J. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. Pract Assess Res Eval. 2005;10(7): 173-178.
17. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J AmAcad Dermatol. 2008;58(6): 1043-1046.
18. PfutzeM, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17(1): 4-11.
19. Frew JW, Murrell DF. Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care. Dermatol Clin. 2010;28(1): 185-190.
20. Sampogna F, Picardi A, Melchi CF, Pasquini P, Abeni D. The impact of skin diseases on patients: comparing dermatologists' opinions with research data collected on their patients. Br J Dermatol. 2003;148(5): 989-995.
21. Martin LK,Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;(1):CD006263.